Statens Serum Institut
Quick facts
Phase 3 pipeline
- C-Tb · Infectious Disease / Immunology
C-Tb is a tuberculosis vaccine candidate that stimulates immune responses against Mycobacterium tuberculosis antigens to prevent or treat tuberculosis infection. - DTaP-IPV mkc vaccine · Immunology
DTaP-IPV mkc vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, and poliovirus through inactivated antigens. - DTaP-IPV vero vaccine · Immunology
This vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, and poliovirus by presenting inactivated antigens. - IPV-Al SSI · Immunology / Infectious Disease
IPV-Al SSI is an inactivated poliovirus vaccine formulated with aluminum adjuvant to stimulate immune response against poliovirus types 1, 2, and 3. - IPV SSI · Immunology / Infectious Disease
IPV SSI is an inactivated poliovirus vaccine that stimulates the immune system to produce antibodies against all three poliovirus serotypes. - Td vaccine SSI · Immunology
The Td vaccine SSI induces immunity against tetanus and diphtheria. - TdaP vaccine SSI · Immunology
The TdaP vaccine SSI works by stimulating the body's immune system to produce antibodies against diphtheria, tetanus, and pertussis.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Statens Serum Institut
What is Statens Serum Institut's pipeline?
Statens Serum Institut has 7 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include C-Tb, DTaP-IPV mkc vaccine, DTaP-IPV vero vaccine, IPV-Al SSI.
Related
- Sector hub: All tracked pharma companies